Source:http://linkedlifedata.com/resource/pubmed/id/17146157
General Info
Affiliation
Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan. keikofuru@triton.ocn.ne.jpAbstract
In breast cancer, HER-2 overexpression suggests s poor prognosis. Trastuzumab is a humanized monoclonal antibody with specificity to the HER-2 protein. We evaluated the safety and efficacy of combined trastuzumab and paclitaxel therapy in women with metastatic breast cancer.
PMID
17146157